Business Context and Reporting Period
Guardant Health, Inc. filed a Form 8-K Current Report dated January 1, 2021. The filing reports the entry into a material definitive agreement on January 1, 2021, involving an amendment to an existing supply contract.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement and does not contain financial performance data.
Material Changes
The primary material change is the execution of Amendment #5 to the Supply Agreement with Illumina, Inc., originally dated September 15, 2014. Key changes include:
- Term Extension: The agreement term is extended to January 2033.
- Renewal Terms: The agreement will automatically renew for successive one-year periods after January 2033 unless terminated or notice of non-renewal is provided at least 12 months in advance.
- Termination Rights: The Company may terminate the agreement for convenience upon 90 days' prior written notice.
- Pricing and Scope: The amendment updated the list of specific hardware and consumables, including associated pricing terms, to be provided by Illumina for the Company's research and clinical activities.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the terms of the agreement. The agreement ensures a continued supply of sequencers, equipment, and materials essential for laboratory operations through 2033, subject to the termination rights noted above.
Investor Verification Checklist
- Verify the full text of Amendment #5 to the Supply Agreement, which is referenced as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
- Review the updated pricing terms for hardware and consumables to assess potential impacts on cost of goods sold.
- Confirm the operational dependency on Illumina for laboratory equipment and materials.